A Research Study to Evaluate BLX-0871 in Healthy Adults

This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance. The main goal is to see if BLX-0871 is safe and well tolerated when given to healthy adults. The study will also measure how the body processes BLX-0871, including how quickly it is absorbed, how long it stays in the blood, and how it is eliminated. Another objective is to see whether food affects the absorption of BLX-0871. It will also look at how the drug affects the body by looking at markers of AMPK activity.

NCT Number	NCT07140081
Lead Sponsor	Biolexis Therapeutics
Conditions	Normal Healthy Adults
Enrollment	76 participants
Start Date	2025-09
Primary Completion	2026-04 (estimated)
Study Completion	2026-05 (estimated)
Updated on ClinicalTrials.gov	2025-08-24